The FDA Has Granted Fast Track Designation To Ionis Pharmaceuticals/Astrazeneca's Eplontersen, An Investigational Therapy For The Treatment Of Transthyretin-mediated Amyloid Cardiomyopathy In Adults
Author: Benzinga Newsdesk | February 08, 2024 08:11am